L9V-16668-17959
3 vaccinations
1 coded response
13 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 946 / CA
- Registered
- 2022-01-11
- Relationship
- Self
- Race
- Black or African American
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-03-26
Dose 1 — Pfizer-BioNTech
-
2021-04-16
Dose 2 — Pfizer-BioNTech
-
2022-01-10
Dose 3 — Pfizer-BioNTech
-
2022-01-11
Registered in v-safe
- 2022-01-11
- 2022-01-12
- 2022-01-13
- 2022-01-15
- 2022-01-16
- 2022-01-17
- 2022-01-24
- 2022-01-31
- 2022-02-07
- 2022-02-14
- 2022-02-21
-
2022-04-11
Survey response — 3 months, dose 3MedDRA: Cough, Headache, Oropharyngeal pain, Pain, Rhinorrhoea, SARS-CoV-2 test positive — Feeling: Poor · Be unable to do your normal daily activitiesFree text: Tested positive for Covid. Symptoms include sore throat, headache, body aches, runny nose and light, dry coughMedDRA releases: 2024-11 · check-in free text available
- 2022-07-11
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-03-26 | Pfizer-BioNTech | No |
| 2 | 2021-04-16 | Pfizer-BioNTech | No |
| 3 | 2022-01-10 | Pfizer-BioNTech | No |
Free text
Release 11 — 3 months, dose 3
Symptoms: Tested positive for Covid. Symptoms include sore throat, headache, body aches, runny nose and light, dry cough
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Cough | · | · | ✓ |
| SD | Headache | · | · | ✓ |
| SD | Oropharyngeal pain | · | · | ✓ |
| SD | Pain | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
| SD | SARS-CoV-2 test positive | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release